ACM
RLMD icon

ADAR1 Capital Management’s Relmada Therapeutics RLMD Stock Holding History

ADAR1 Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Hold
451,918
– – 0.14% 127
2026
Q1 		$3.15M Buy
451,918
+421,052
+1,364% +$1.99M 0.19% 104
2025
Q4 		$149K Buy
+30,866
New +$103K 0.01% 235
2025
Q3 		– Sell
-130,000
Closed -$78K – 252
2025
Q2 		$78K Buy
+130,000
New +$66.7K 0.01% 184
2024
Q3 		– Sell
-50,601
Closed -$152K – 331
2024
Q2 		$152K Buy
50,601
+50,000
+8,319% +$181K 0.03% 154
2024
Q1 		$2.79K Sell
601
-58,000
-99% -$279K ﹤0.01% 245
2023
Q4 		$243K Buy
+58,601
New +$174K 0.09% 79

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's RLMD Position: Q2 2026 in Review

ADAR1 Capital Management held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 451,918 shares worth $3.13M. The position accounts for 0.14% of the portfolio, ranked #127.

ADAR1 Capital Management first reported a position in RLMD in Q4 2023 and has held it in 7 quarters since. The position peaked at $3.15M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • ADAR1 Capital Management held 451,918 shares of Relmada Therapeutics worth $3.13M as of Q2 2026.
  • ADAR1 Capital Management left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.14% of ADAR1 Capital Management's portfolio in Q2 2026, its #127 holding.
  • ADAR1 Capital Management first reported a position in Relmada Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • ADAR1 Capital Management's Relmada Therapeutics position peaked at $3.15M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.